Literature DB >> 34907716

Prevalence of Fabry disease in men with tinnitus and sensorineural hearing loss.

Richard Holy1, Tereza Hlozkova2, Klara Prochazkova3, David Kalfert4, Frantiska Hybnerova1, Denisa Ebelova5, Berthold Streubel6, Martin Chovanec3, Bretislav Gal2, Ales Linhart5, Jaromir Astl1.   

Abstract

Fabry disease (FD) is a lysosomal storage disorder caused by pathogenic mutations in the alpha-galactosidase A (AGALA) encoding gene region. This rare disease affects several organs including the cochlea-vestibular system. Tinnitus and sensorineural hearing loss (SNHL) are reported among otoneurological symptoms. Early and correct diagnosis of FD is important with a view to available therapy. The aim of the study was to screen for alpha-galactosidase deficiency in men with tinnitus/SNHL. A prospective multicentric study including consecutive patients with SNHL confirmed by tone audiometry or tinnitus evaluated (10/2016-8/2019). The diagnosis of AGALA deficiency was done by dry blood spot method using a threshold of 1.2 µmol/l/h. Only men aged 18-60 were included. 181 patients were subject to evaluation. SNHL was reported in 126 (70%) patients, 50 (28%) patients had unilateral, 76 (42%) patients had bilateral SNHL. Tinnitus was found in 161 (89%) patients, unilateral in 96 (53%) and bilateral in 65 (36%) patients. Suspected FD was not detected in any patient; alpha-galactosidase The AGALA values ranged 1.5-8.8 µmol/l/h, an average of 3.4 µmol/l/h. None of the 181 patients participating in the study had AGALA levels below the threshold 1.2 µmol/l/h. The occurrence of tinnitus and sensorineural hearing loss in men appears to be an irrelevant clinical sign for FD systematic screening.

Entities:  

Keywords:  Alpha-galactosidase; Fabry disease; Screening; Sensorineural hearing loss; Tinnitus

Mesh:

Substances:

Year:  2021        PMID: 34907716     DOI: 10.32725/jab.2021.003

Source DB:  PubMed          Journal:  J Appl Biomed        ISSN: 1214-021X            Impact factor:   1.797


  18 in total

1.  A new phenotype of Fabry disease with intermediate severity between the classical form and the cardiac variant.

Authors:  D P Germain
Journal:  Contrib Nephrol       Date:  2001       Impact factor: 1.580

Review 2.  Sudden sensorineural hearing loss.

Authors:  G B Hughes; M A Freedman; T J Haberkamp; M E Guay
Journal:  Otolaryngol Clin North Am       Date:  1996-06       Impact factor: 3.346

3.  Hearing loss in Fabry disease: data from the Fabry Outcome Survey.

Authors:  S Hegemann; D Hajioff; G Conti; M Beck; G Sunder-Plassmann; U Widmer; A Mehta; A Keilmann
Journal:  Eur J Clin Invest       Date:  2006-09       Impact factor: 4.686

4.  Allograft loss in renal transplant recipients with Fabry's disease and activated protein C resistance.

Authors:  G S Friedman; D Wik; L Silva; J C Abdou; H U Meier-Kriesche; B Kaplan; L Bonomini; P DeFranco; N Lyman; S Mulgaonkar; M Jacobs
Journal:  Transplantation       Date:  2000-05-27       Impact factor: 4.939

Review 5.  Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy.

Authors:  Robert J Desnick; Roscoe Brady; John Barranger; Allan J Collins; Dominique P Germain; Martin Goldman; Gregory Grabowski; Seymour Packman; William R Wilcox
Journal:  Ann Intern Med       Date:  2003-02-18       Impact factor: 25.391

6.  Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A).

Authors:  Wuh-Liang Hwu; Yin-Hsiu Chien; Ni-Chung Lee; Shu-Chuan Chiang; Robert Dobrovolny; Ai-Chu Huang; Hui-Ying Yeh; May-Chin Chao; Shio-Jean Lin; Teruo Kitagawa; Robert J Desnick; Li-Wen Hsu
Journal:  Hum Mutat       Date:  2009-10       Impact factor: 4.878

7.  Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.

Authors:  D A Hughes; P M Elliott; J Shah; J Zuckerman; G Coghlan; J Brookes; A B Mehta
Journal:  Heart       Date:  2007-05-04       Impact factor: 5.994

8.  Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy.

Authors:  D Hajioff; Y Enever; R Quiney; J Zuckerman; K Mackermot; A Mehta
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

9.  Hearing improvement in patients with Fabry disease treated with agalsidase alfa.

Authors:  D Hajioff; S Goodwin; R Quiney; J Zuckerman; K D MacDermot; A Mehta
Journal:  Acta Paediatr Suppl       Date:  2003-12

10.  Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease.

Authors:  Lubor Goláň; Ozlem Goker-Alpan; Myrl Holida; Ikka Kantola; Mariusz Klopotowski; Johanna Kuusisto; Aleš Linhart; Jacek Musial; Kathleen Nicholls; Derlis Gonzalez-Rodriguez; Reena Sharma; Bojan Vujkovac; Peter Chang; Anna Wijatyk
Journal:  Drug Des Devel Ther       Date:  2015-07-08       Impact factor: 4.162

View more
  1 in total

1.  Fabry Disease in Slovakia: How the Situation Has Changed over 20 Years of Treatment.

Authors:  Katarina Jurickova; Petra Jungova; Robert Petrovic; Slavomira Mattosova; Tereza Hlavata; Ludmila Kostalova; Anna Hlavata
Journal:  J Pers Med       Date:  2022-06-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.